Parkinson Disease

SPN-830, an apomorphine infusion device, had its new drug application submitted using data from the phase 3 TOLEDO trial.

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

Findings from a recent study revealed the significant influence of lysosomal polygenic burden on cognitive decline in patients Parkinson disease who also have a low risk of Alzheimer disease.

Although results from the phase 2 LixiPark trial showed that lixisenatide may slow motor symptom progression in early Parkinson disease, reported gastrointestinal adverse effects raise some safety considerations.

Zoltan Mari, MD, shares advice and tips to physicians and patients for the use of wearable devices in PD.

An expert neurologist highlights resources for patients and physicians to gain access to wearable devices to aide with management of PD.

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders.

The randomized, double-blind, placebo-controlled trial failed to show any beneficial symptomatic effect of 4-month treatment with 1.75–3.5 mg/day bumetanide on Parkinson disease.

The findings were consistent with the chemical's known carcinogenicity and supportive of the emerging preclinical and epidemiological evidence that ties TCE exposure to patients with PD.

A recent study revealed that digital composite measures for bradykinesia outperformed traditional assessment methods for Parkinson disease over a 12-month period.

Zoltan Mari, MD, provides an overview of the use of smartphone applications to help patients manage PD, highlighting a keyboard typing assistance app.

An expert neurologist discusses sensory-based wearable devices used to control PD symptoms, commenting on challenges with these devices.

At AD/PD 2024, AC Immune SA presented an update on the company's phase 2 VacSYn trial assessing ACI-7104.056, an anti-α-synuclein active immunotherapy, for patients with Parkinson disease.

It’s hard to be in medicine at the moment, and one day’s recognition is not enough. As your peer, I honor my fellow physicians today and every day.

New data presented at the 2024 AD/PD Conference revealed the potential of smartphone speech analysis metrics as a biomarker for hypokinetic dysarthria in early Parkinson disease.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Recent data highlighted the benefit of Gain Therapeutics’ GT-02287 mechanism of action in alleviating endoplasmic reticulum stress and enhancing lysosomal enzyme activity.

A phase 2a trial demonstrated significant cognitive improvement in patients with mild cognitive impairment or mild dementia from Alzheimer or Parkinson disease through combination adrenergic activator therapy.

Zoltan Mari, MD, dives deeper into tremors, a troublesome feature of PD, and what devices are available and upcoming to diagnose, monitor, and control tremors.

Zoltan Mari, MD, reviews the available wearable devices used to monitor bradykinesia and dyskinesia in patients with PD, as well as benefits and challenges associated with the devices.

The phase 2 study for risvodetinib in Parkinson disease aims to halt disease progression and reverse functional loss.

This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.

In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.

A 24-hour subcutaneous infusion of ND0612 was superior to oral immediate-release levodopa–carbidopa at increasing on time without troublesome dyskinesia and reducing off time in adults with Parkinson disease.

New findings from a phase 1 trial presented at AD/PD 2024 showed that UB-312 antibodies decrease α-synuclein levels in the cerebrospinal fluid of patients with Parkinson disease.